Virax Biolabs logo
Virax Biolabs
VRAX | NASDAQ
Chart Builder DCF Calculator
$0.45
-$0.16 (-26.54%)
At close: Nov 16, 2026, 4:00 PM ET
$0.43
-$0.02 (-4.16%)
After-hours: Nov 16, 2026, 7:30 PM ET

Virax Biolabs Company Profile

Company profile explained

Company Profile

Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The company is developing T cell-based test technologies intended to support an immunology profiling platform, with potential applications in post-acute infection syndromes, including Long COVID, and other chronic conditions linked to immune dysregulation.

Key Executives

Name Position
James Foster Chairman, Chief Executive Officer & Principal Accounting Officer
Nigel McCracken Chief Operating Officer & Director
Clement Monteil Head of Scientific Research & Development
Lily Fu Head of Supply Chain

Latest SEC Filings

Date Type Title
Oct 29, 2026 6-K Filing
Oct 21, 2026 3 Filing
Oct 09, 2026 6-K Filing
Sep 10, 2026 424B3 Filing
Sep 04, 2026 6-K Filing
Sep 04, 2026 424B5 Filing
Sep 03, 2026 EFFECT Filing
Sep 02, 2026 F-3/A [Amend] Filing
Aug 26, 2026 6-K Filing
Aug 18, 2026 6-K Filing
View All SEC Filings ➞
Virax Biolabs
Virax Biolabs logo
Country United Kingdom
IPO Date Jul 21, 2022
Industry Biotechnology
Sector Healthcare
Employees 26
CEO James Foster

Contact Details

BioCity Glasgow Lanarkshire, South Carolina ML1 5UH United Kingdom

Stock Details

Ticker Symbol VRAX
Exchange NASDAQ
Fiscal Year April - March
Reporting Currency USD
CIK Code 0001885827
CUSIP Number G9495L133
ISIN Number KYG9495L1335
SIC Code 2835

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.